

## Highlights of This Issue 1125

### REVIEW

- 1127 | **Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools**  
Olaf Merkel, Frank Hamacher, Eveline Sifft, Lukas Kenner, and Richard Greil  
for the European Research Initiative on Anaplastic Large Cell Lymphoma

### THERAPEUTIC DISCOVERY

- 1137 | **Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells**  
Chunyu Zhang, Abdel G. Elkahoun, Hongling Liao, Shannon Delaney, Barbara Saber, Betsy Morrow, George C. Prendergast, M. Christine Hollander, Joell J. Gills, and Phillip A. Dennis

- 1149 | **Silencing IL-13R $\alpha$ 2 Promotes Glioblastoma Cell Death via Endogenous Signaling**  
Linda C. Hsi, Suman Kundu, Juan Palomo, Bo Xu, Ryan Ficco, Michael A. Vogelbaum, and Martha K. Cathcart

- 1161 | **Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy**  
Ashutosh Shrivastava, Paula M. Kuzontkoski, Jerome E. Groopman, and Anil Prasad

### PRECLINICAL DEVELOPMENT

- 1173 | **Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents**  
Qingbei Zhang, Vytas Bindokas, Jikun Shen, Hanli Fan, Robert M. Hoffman, and H. Rosie Xing

- 1185 | **Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation**  
Juan Camilo Barreto-Andrade, Elena V. Efimova, Helena J. Mauceri, Michael A. Beckett, Harold G. Sutton, Thomas E. Darga, Everett E. Vokes, Mitchell C. Posner, Stephen J. Kron, and Ralph R. Weichselbaum

- 1194 | **Hsp90 Inhibitor-Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage**  
Kyungsoo Ha, Warren Fiskus, Rekha Rao, Ramesh Balusu, Sreedhar Venkannagari, Narasimha Rao Nalabothula, and Kapil N. Bhalla

- 1207 | **Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue**  
Veronica Novotny-Diermayr, Nina Sausgruber, Yung Kiang Loh, Mohammed Khalid Pasha, Ramesh Jayaraman, Hannes Hentze, Wei-Peng Yong, Boon-Cher Goh, Han-Chong Toh, Kantharaj Ethirajulu, Joy Zhu, and Jeanette Marjorie Wood

- 1218 | **E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor**  
Hirokazu Ogino, Masaki Hanibuchi, Soji Kakiuchi, Van The Trung, Hisatsugu Goto, Kenji Ikuta, Tadaaki Yamada, Hisanori Uehara, Akihiko Tsuruoka, Toshimitsu Uenaka, Wei Wang, Qi Li, Shinji Takeuchi, Seiji Yano, Yasuhiko Nishioka, and Saburo Sone

- 1229 | **Characterization of the Oncogenic Activity of the Novel TRIM59 Gene in Mouse Cancer Models**  
Fatma Valiyeva, Fei Jiang, Ahmed Elmaadawi, Madeleine Moussa, Siu-Pok Yee, Leda Raptis, Jonathan I. Izawa, Burton B. Yang, Norman M. Greenberg, Fen Wang, and Jim W. Xuan

1241 | **Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins**

Arti Yadav, Bhavna Kumar, Theodoros N. Teknos, and Pawan Kumar

1252 | **Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance *In Vitro* and *In Vivo***

Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Hiroshi Hatano, Yoshiaki Igarashi, Naoyuki Asakawa, Hiroshi Kodaira, Hiroyuki Takahashi, Ritsuo Aiyama, Takeshi Matsuzaki, Nao Yagi, and Yoshikazu Sugimoto

1264 | **Synergistic Antitumor Activity of Gemcitabine and ABT-737 *In Vitro* and *In Vivo* through Disrupting the Interaction of USP9X and Mcl-1**

Chong Zhang, Tian-yu Cai, Hong Zhu, Liu-qing Yang, Hai Jiang, Xiao-wu Dong, Yong-zhou Hu, Neng-ming Lin, Qiao-jun He, and Bo Yang

1276 | **Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells**

Hong Zhou, John W. Marks, Walter N. Hittelman, Hideo Yagita, Lawrence H. Cheung, Michael G. Rosenblum, and Jeffrey A. Winkles

## MOLECULAR MEDICINE IN PRACTICE

1289 | **Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer**


Raquel De Souza, Payam Zahedi, Rose M. Badame, Christine Allen, and Micheline Piquette-Miller

1300 | **Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin-Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity**

Siqing Fu, Aung Naing, Stacy L. Moulder, Kirk S. Culotta, David C. Madoff, Chaan S. Ng, Timothy L. Madden, Gerald S. Falchook, David S. Hong, and Razelle Kurzrock

## ABOUT THE COVER

A novel *TRIM* family member *TRIM59* has proto-oncogenic activity in a transgenic mouse prostate cancer modeling test. Restricted *TRIM59* gene expression in the mouse prostate using a prostate tissue-specific gene (*PSP94*) revealed the full potential for tumorigenesis and developed poorly differentiated cancer of the prostate and comedocarcinoma, which had features of neurocarcinoma (small cell carcinoma) and central necrosis. The *PSP94-TRIM59* mice coincided with the upregulation of genes specific to the Ras signaling pathway and bridging genes for SV40Tag-mediated oncogenesis. For details, see the article by Valiyeva and colleagues on page 1229.



# Molecular Cancer Therapeutics

**10 (7)**

*Mol Cancer Ther* 2011;10:1125-1307.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/10/7>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/10/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.